Today is Wear Brown Shoes Day! What a holiday! Dust off those beautiful brown loafers, boots, flip flops or slippers and show the world today is Wear Brown Shoes Day!

This issue of In The Know covers new Therapeutic Substances that were added for FY2018 PCS codes mentioned in Coding Clinic Fourth Quarter, 2017.


Bezlotoxumab Monoclonal Antibody - ZINPLAVA

Device/Substance/Technology Character A

This new drug is used in addition to an antibiotic for Clostridium difficile infection – but are at high risk for recurrence. This IV substance targets toxins produced by Clostridium difficile bacteria.

Coding Clinic, 4th Qtr 2017, pg 77


Cytarine and Daunorubicin Liposome Antineoplastic– VYXEOS

Device/Substance/Technology Character B

This new drug for injection is a specific formula that is a combination of the drugs Cytarabine and Daunorubicin, These chemotherapy drugs are used in concurrent dosing regimen to induce remission of acute myeloid leukemia.

Coding Clinic, 4th Qtr 2017, pg 77


Axicabtagene Ciloleucel – KTE-C19

Device/Substance/Technology Character C

Engineered Autologous Chimeric Antigen Receptor T-Cell Immunotherapy is used to treat patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma who do not qualify for autologous stem cell transplant. T-cells are harvested from the patient – then engineered using a “chimeric antigen receptor construct” to target specific antigens that are a part of B-cell lymphoma. The engineered T-cells are infused back into the patient to destroy their targets.

Coding Clinic, 4th Qtr 2017, pgs 77-78


Other New Technology Therapeutic Substance

Device/Substance/Technology Character F

Character F was added to the rows for body part values describing Central and Peripheral Vein for assignment of new technology intravenous drugs when no specific code is available.

Coding Clinic, 4th Qtr 2017, pg 78